Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Sangui BioTech International Inc., US80105B1017

Sangui BioTech International Inc., US80105B1017

15.11.2019 - 13:58:22

Sangui BioTech International Inc.: - Significant cost reductions in the first quarter; - Mölnlycke invests in warehouse capacities

 

Sangui BioTech:

- Significant cost reductions in the first quarter

- Mölnlycke invests in warehouse capacities

Hamburg, November, 15 2019: In the first three months of fiscal year 2020 (to 30/06/2020) Sangui BioTech International Inc. achieved revenues from royalty income of USD 282. In the same period of the previous year the comparable revenue amounted to USD 11,272. Due to lower revenues of the wound spray Granulox, the resulting royalty income in the first three month of the year was significantly below the level of the same period of the previous year.

Responsible for this development were measures for the integration of the licensee, SastoMed GmbH into the Mölnlycke Group. In particular, the restructuring of the sales and distribution channels in the Mölnlycke Group has taken some time. Necessary investments in new warehouse capability to meet future demands have meanwhile been completed. Mölnlycke believes that these measures will bear fruit with respect to revenue.

As operating expenses decreased USD 48,517 or 46% to USD 56,180 during the period, three month operating loss decreased USD 37,600 to USD 55,898 from the prior year. The reason for this was cost savings in connection with the closure of the Witten site.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact: Sangui Biotech International, Inc. Thomas Striepe e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

15.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

914467  15.11.2019 

@ dgap.de